This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Mavenclad (cladribine)
General Description:
Mavenclad (cladribine) is an oral medication indicated for the treatment of relapsing forms of multiple sclerosis (MS). It is designed to selectively target and reduce B and T lymphocytes, key immune cells that drive the inflammatory process in MS, while largely sparing the innate immune system.
Mavenclad offers a short-course oral dosing regimen that provides lasting effects on disease activity, helping to reduce relapses and slow disease progression.
Estimated delivery time for this product is between 5 and 10 working days.
Disease Indications:
Multiple Sclerosis (MS)
Manufacturer:
Merck Serono Europe Limited
Usage:
Oral
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Health Canada
• Therapeutic Goods Administration (TGA)
• Medsafe (New Zealand)
Package:
• 1 tablet × 10 mg
• 4 tablets × 10 mg
• 6 tablets × 10 mg
Shipping:
Room Temperature Shipping
Mavenclad is stable at room temperature and does not require refrigeration. It is shipped under standard temperature-controlled conditions (15°C to 25°C) to preserve product quality and potency during transit.
This standard shipping method is cost-effective while ensuring that Mavenclad remains safe, stable, and fully effective upon delivery.
How to Access Mavenclad (cladribine) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Mavenclad (cladribine) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
